Revised diagnostic criteria of multiple sclerosis

Milo, Ron; Miller, David H.

doi:10.1016/j.autrev.2014.01.012

Cited by 245 publications

(178 citation statements)

References 38 publications

Supporting

Mentioning

169

Contrasting

Unclassified

Order By: Relevance

“…Patients:-Sixty eight Iraqi Arab Muslim patients were diagnosed as relapsing-remitting multiple sclerosis (RRMS) patients by physicians according to McDonald criteria 2010 revision (Milo and Miller, 2014) at Multiple Sclerosis Clinic (Baghdad Teaching Hospital). The patients were distributed as: 30 pre-medicated patients (did not receive the immunomodulatory drug IFNβ or corticosteroids) and 38 patients received IFNβ (post-medicated).…”

Section: Materials and Methods:-mentioning

confidence: 99%

WHAT IS THE IMPACT OF IL12B+1188 SINGLE NUCLEOTIDE POLYMORPHISM ON IL-12 SERUM LEVEL of MULTIPLE SCLEROSIS IRAQI PATIENTS?

Al-Nasiri¹,

Salman²,

Ad’hiah³

et al. 2016

IJAR

View full text Add to dashboard Cite

Multiple sclerosis, IL-12 serum level, Single nucleotide polymorphism.Multiple sclerosis (MS) is a chronic neurodegenerative disease that results from interaction between genetic, epigenetic, and environmental factors, and affects especially young adults. Serum level and single nucleotide polymorphism (SNP) of Interleukin-12 (IL-12) were determined in 68 relapsing-remitting MS Iraqi patients and 20 healthy individuals, matched patients for ethnicity, age and gender. The patients were distributed into IFNβ pre-and postmedicated patients, in addition, extended disability status scale (EDSS) was also applied as a parameter for distribution. The results indicated that there were significant differences in serum levels of IL-12 among the three investigated groups; pre-and post-medicated patients and controls (35.9 ± 1.6 vs. 29.5 ± 2.4 vs. 22.7 ± 2.9 pg/ml, respectively). However, there was no significant effect of EDSS on the level of IL-12 in pre-and post-medicated patients. IL12B gene SNP at position +1188 was presented with three genotypes (AA, AC and CC), which showed a significant difference between the observed and expected genotype frequencies (p ≤ 0.01) in patients, while a good agreement with Hardy-Weinberg equilibrium was observed in controls. However, there was no significant variation between patients and controls in the distribution of IL12B +1188 allele and genotype frequencies; although CC genotype was observed with a frequency of 17.9% in MS patients, while none of the controls possessed this genotype, and the odds ratio of such difference was 9.23. A significant impact of IL12B +1188 SNP on IL-12 serum level was recorded in MS patients carrying CC and AC genotypes (27

show abstract

Section: Materials and Methods:-mentioning

confidence: 99%

WHAT IS THE IMPACT OF IL12B+1188 SINGLE NUCLEOTIDE POLYMORPHISM ON IL-12 SERUM LEVEL of MULTIPLE SCLEROSIS IRAQI PATIENTS?

Al-Nasiri¹,

Salman²,

Ad’hiah³

et al. 2016

IJAR

View full text Add to dashboard Cite

show abstract

“…Notably, however, in patients with clinically isolated syndrome (CIS), CSF OCBs help define the risk of MS conversion with 91% sensitivity and 94% specificity [13], with greater accuracy vs the criterion of dissemination in space on brain MRI (70 vs 58%) and improvement of global diagnostic accuracy [14]. Most importantly, the exclusion of alternative diagnosis, which requires CSF analysis, is also fundamental in CIS patients [15] and in general in patients with suspected CNS inflammatory diseases.…”

Section: Multiple Sclerosis and Oligoclonal Bandsmentioning

confidence: 99%

Cerebrospinal fluid analysis and the determination of oligoclonal bands

Gastaldi

Zardini

Leante³

et al. 2017

Neurol Sci

View full text Add to dashboard Cite

This document presents the guidelines for the cerebrospinal fluid (CSF) analysis and the determination of oligoclonal bands (OCBs) as pivotal tests in neuroin flammatory pathologies of the central nervous system. The guidelines have been developed following a consensus process built on questionnaire-based surveys, internet contacts, and discussions at workshops of the sponsoring Italian Association of Neuroimmunology (AINI) congresses. Essential clinical information on the pathologies in which the CSF analysis is indicated, and, particularly, on those characterized by the presence of OCBs in the intrathecal compartment, indications and limits of CSF analysis and OCB determination, instructions for result interpretation, and agreed laboratory protocols (Appendix) are

show abstract

“…The rate of conversion from CIS to RRMS at 20 years is 21% of patients with a normal MRI scan at baseline versus 82%, if there is one or more clinically silent white matter lesions on MRI. 9,13 It has been shown that the McDonald 2010 criteria and increased use of MRI are revolutionising the diagnoses of clinically definite MS for the CIS group. 14 With RRMS there is usually good recovery from each clinical episode or relapse.…”

Section: Subtypes Of Msmentioning

confidence: 99%

“…The 2010 revisions to the McDonald diagnostic criteria advise that there could be additional evidence of dissemination of MS lesions in time and in space, shown by MRI evidence. [7][8][9] Many other MRI indices exist, eg T1 black holes, or are being developed, eg atrophy measures of reduction in brain volume, although these are not yet incorporated fully into standard clinical practice. 3,10 The diagnosis of MS can be further reinforced by paraclinical data in the form of increased latency of evoked potentials, eg visual evoked potentials, and lumbar puncture with the assessment of unmatched oligoclonal immunoglobulin IgG bands in the cerebrospinal fluid (CSF) that are seen in up to 90% of MS patients.…”

mentioning

confidence: 99%

Multiple sclerosis, a treatable disease

Doshi

Chataway

2017

Clinical Medicine

View full text Add to dashboard Cite

This article reviews our current understanding and modern treatment of multiple sclerosis (MS). MS is a disabling condition resulting in devastating social and economic impacts. As MS can affect any part of the central nervous system, the presentation is often diverse; however, there are key features that can be useful in the clinic. We comment on the diagnostic criteria and review the main subtypes of MS, including clinically isolated syndrome, relapsing remitting MS, secondary progressive MS and primary progressive MS. Although the underlying aetiology of MS is still not known, we summarise those with most evidence of association. Finally, we aim to present treatment strategies for managing the acute relapse, disease-modifying therapies and MS symptoms. This review highlights that progressive MS is an area where there is currently a paucity of available diseasemodifying treatments and this will be a major focus for future development.KEYWORDS : Diagnostic criteria , epidemiology , multiple sclerosis , progressive multiple sclerosis , treatments What is multiple sclerosis?Multiple sclerosis (MS) is an acquired disabling neurological disease of young adults, affecting approximately 2.3 million people worldwide. It is most prevalent in North America (140 cases per 100,000) and Europe (108 cases per 100,000); the prevalence is lowest in sub-Saharan Africa (2.1 cases per 100,000) and East Asia (2.2 cases per 100,000).1 Overall, there are approximately 120,000 people with MS in the UK. 2MS is an inflammatory disease of the central nervous system (CNS), which causes a heterogeneous array of symptoms and signs because of differential involvement of motor, sensory, visual and autonomic systems. Optic neuritis (inflammation of the optic nerve), Uhthoff's phenomenon (transient fluctuation or worsening of MS symptoms with a rise in body temperature) and Lhermitte's phenomenon (an abnormal electric-shock like sensation down the spine or limbs on neck flexion) are characteristic of MS.3-5 MS relapses occur because of focal areas ABSTRACTMultiple sclerosis, a treatable disease of demyelination evolving over 24 hours and persisting for days or weeks before generally, though not exclusively, improving.4,6

show abstract

Revised diagnostic criteria of multiple sclerosis

Cited by 245 publications

References 38 publications

WHAT IS THE IMPACT OF IL12B+1188 SINGLE NUCLEOTIDE POLYMORPHISM ON IL-12 SERUM LEVEL of MULTIPLE SCLEROSIS IRAQI PATIENTS?

WHAT IS THE IMPACT OF IL12B+1188 SINGLE NUCLEOTIDE POLYMORPHISM ON IL-12 SERUM LEVEL of MULTIPLE SCLEROSIS IRAQI PATIENTS?

Cerebrospinal fluid analysis and the determination of oligoclonal bands

Multiple sclerosis, a treatable disease

Contact Info

Product

Resources

About